The American Cancer Society estimates that in 2024, there will be 2,001,140 new cancer cases and 611,720 cancer deaths in the United States. Cancer mortality has continued to decline since 1991 due to reduced smoking, earlier detection, and improved treatments. However, incidence rates for six of the top 10 cancers have increased. Rates for breast, pancreas, and uterine corpus cancers increased by 0.6%–1% annually, while rates for prostate, liver, kidney, and HPV-associated oral cancers, and melanoma increased by 2%–3% annually. Rates for cervical and colorectal cancers in young adults also increased by 1%–2% annually. Colorectal cancer is now the leading cause of cancer death in men and second in women. Persistent cancer disparities exist, with Black people having two-fold higher mortality rates for prostate, stomach, and uterine corpus cancers, and Native American people having higher rates for liver, stomach, and kidney cancers compared to White people. Continued progress requires investment in cancer prevention and equitable treatment, especially for American Indian and Alaska Native and Black individuals. Cancer incidence data is collected by the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program and the Centers for Disease Control and Prevention's National Program of Cancer Registries. Mortality data is provided by the National Center for Health Statistics. Incidence and mortality rates are age-standardized to the 2000 US standard population. The probability of developing cancer is calculated using the NCI's DevCan software, and trends are analyzed using the NCI's Joinpoint Regression Program. Delay adjustment is important for accurate trend analysis, especially for cancers frequently diagnosed in outpatient settings. In 2024, the estimated number of new cancer cases is 2,001,140, with 56,500 new cases of ductal carcinoma in situ in women and 99,700 new cases of melanoma in situ. The estimated number of cancer deaths is 611,720, with the highest number of deaths from lung, colorectal, and pancreatic cancers. The number of cancer deaths averted since 1991 is estimated at over 4 million. Cancer survival rates have increased significantly, with the 5-year relative survival rate for all cancers combined increasing from 49% in the mid-1970s to 69% in 2013–2019. Survival rates are highest for thyroid, prostate, testis, and melanoma cancers and lowest for pancreatic, liver and esophageal, and lung cancers. Survival gains for hematopoietic and lymphoid malignancies are due to improved treatment protocols, including targeted therapies and immunotherapies. Survival for metastThe American Cancer Society estimates that in 2024, there will be 2,001,140 new cancer cases and 611,720 cancer deaths in the United States. Cancer mortality has continued to decline since 1991 due to reduced smoking, earlier detection, and improved treatments. However, incidence rates for six of the top 10 cancers have increased. Rates for breast, pancreas, and uterine corpus cancers increased by 0.6%–1% annually, while rates for prostate, liver, kidney, and HPV-associated oral cancers, and melanoma increased by 2%–3% annually. Rates for cervical and colorectal cancers in young adults also increased by 1%–2% annually. Colorectal cancer is now the leading cause of cancer death in men and second in women. Persistent cancer disparities exist, with Black people having two-fold higher mortality rates for prostate, stomach, and uterine corpus cancers, and Native American people having higher rates for liver, stomach, and kidney cancers compared to White people. Continued progress requires investment in cancer prevention and equitable treatment, especially for American Indian and Alaska Native and Black individuals. Cancer incidence data is collected by the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program and the Centers for Disease Control and Prevention's National Program of Cancer Registries. Mortality data is provided by the National Center for Health Statistics. Incidence and mortality rates are age-standardized to the 2000 US standard population. The probability of developing cancer is calculated using the NCI's DevCan software, and trends are analyzed using the NCI's Joinpoint Regression Program. Delay adjustment is important for accurate trend analysis, especially for cancers frequently diagnosed in outpatient settings. In 2024, the estimated number of new cancer cases is 2,001,140, with 56,500 new cases of ductal carcinoma in situ in women and 99,700 new cases of melanoma in situ. The estimated number of cancer deaths is 611,720, with the highest number of deaths from lung, colorectal, and pancreatic cancers. The number of cancer deaths averted since 1991 is estimated at over 4 million. Cancer survival rates have increased significantly, with the 5-year relative survival rate for all cancers combined increasing from 49% in the mid-1970s to 69% in 2013–2019. Survival rates are highest for thyroid, prostate, testis, and melanoma cancers and lowest for pancreatic, liver and esophageal, and lung cancers. Survival gains for hematopoietic and lymphoid malignancies are due to improved treatment protocols, including targeted therapies and immunotherapies. Survival for metast